The antisense concept has been around for 30 years and now therapies are on the market and in the clinic, including a recently reported Phase IIa trial by Melbourne company Antisense Therapeutics. [ + ]

Arana files IND application for rheumatoid arthritis candidate [ + ]

Astronomer named as new chief scientist [ + ]

Unlisted Queensland biotech Xenome has reported good results in a Phase II trial of its candidate for chronic cancer pain relief and raised a good amount of cash to further its clinical development. [ + ]

Astronomer Professor Penny Sackett has been appointed as Australia's new full-time Chief Scientist.

Western Australian company Orthocell is pioneering biological therapies to repair and regenerate damaged tendons and ligaments. [ + ]

Monash University's Protein Crystallography Unit is being upgraded with a new automated protein crystallisation system, an imaging plate dectector and an HF X-ray source.

Xenome starts Phase II for acute post-operative pain [ + ]

Phosphagenics to delist from AIM, starts Phase I for delivery system [ + ]

BioProspects names new CEO [ + ]

HeartWare gets FDA approval for investigational device [ + ]

Arana develops new anti-inflammatory antibody candidate, prepares for clinic [ + ]

Clinuvel to test CUV1657 as adjunct therapy in cancer patients [ + ]

Francis Gurry appointed head of UN IP agency [ + ]

GTG board in the dark about Jacobson spill attempt, goes to the dogs [ + ]